Abcellera Biologics Inc ABCL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:46 PM EDT
3.88quote price arrow up+0.04 (+1.02%)
Volume
3,897
Close
3.84quote price arrow down-0.20 (-4.95%)
Volume
1,328,190
52 week range
3.62 - 8.05
Loading...
  • Open4.04
  • Day High4.20
  • Day Low3.78
  • Prev Close4.04
  • 52 Week High8.05
  • 52 Week High Date07/19/23
  • 52 Week Low3.62
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap1.129B
  • Shares Out293.92M
  • 10 Day Average Volume1.66M
  • Dividend-
  • Dividend Yield-
  • Beta0.44
  • YTD % Change-32.75

KEY STATS

  • Open4.04
  • Day High4.20
  • Day Low3.78
  • Prev Close4.04
  • 52 Week High8.05
  • 52 Week High Date07/19/23
  • 52 Week Low3.62
  • 52 Week Low Date04/25/24
  • Market Cap1.129B
  • Shares Out293.92M
  • 10 Day Average Volume1.66M
  • Dividend-
  • Dividend Yield-
  • Beta0.44
  • YTD % Change-32.75

RATIOS/PROFITABILITY

  • EPS (TTM)-0.51
  • P/E (TTM)-7.59
  • Fwd P/E (NTM)-6.03
  • EBITDA (TTM)-209.505M
  • ROE (TTM)-12.27%
  • Revenue (TTM)38.026M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-384.99%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Abcellera Biologics Inc

 

Profile

MORE
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work...
Carl Hansen Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Andrew Booth
Chief Financial Officer
Address
2215 Yukon Street
Vancouver, BC
V5Y 0A1
Canada

Top Peers

SYMBOLLASTCHG%CHG
BCYC
Bicycle Therapeutics PLC
23.62+0.54+2.34%
PHVS
Pharvaris NV
20.85-1.77-7.82%
CGEM
Cullinan Therapeutics Inc
27.72-1.63-5.55%
SRRK
Scholar Rock Holding Corp
14.50-0.19-1.29%
FDMT
4D Molecular Therapeutics Inc
26.33-0.47-1.75%